EU IVDR Classification Rules 1 to 7 Explained

1. Key takeaways

The seven rules in Section 2 of Annex VIII determine the class of almost every IVD. Rule 1 places in Class D devices for blood donor screening, for detecting pathogens that cause life-threatening diseases with high or suspected high risk of transmission, and for monitoring infection load in life-threatening diseases. Under Rule 2, blood grouping and tissue typing are Class C, but ABO, Rh, Kell, Kidd and Duffy markers are Class D. Rule 3 lists 13 Class C purposes. Under Rule 4, self-tests are Class C, with pregnancy, fertility, cholesterol and urine glucose, urine red and white blood cells, and urine bacteria as Class B exceptions, while near-patient devices are classified on their own merits. Rule 5 yields Class A; Rule 6 is the residual Class B rule; and under Rule 7, control materials without assigned values are Class B.

Working the rules in sequence, with written reasons for applying or excluding each one, is the only defensible method. Product-family analogy, however common in practice, produces misclassification exactly at the borderline cases that notified bodies examine first.

2. Legal basis

The table below lists the sources for rule-based classification under Annex VIII.

Classification under the rules feeds directly into the Article 48 conformity assessment routes, so the rule-by-rule analysis is part of the technical documentation, not an internal side memo.

3. Expert insights

Insight 1: Rule 1 turns on consequences, not on the identity of the pathogen.

The three limbs of Rule 1 share one feature: an erroneous result would directly cause transmission or a fatal outcome. They cover devices for detecting infectious agents to assess whether blood, blood components, cells, tissues or organs are suitable for transfusion, transplantation or cell administration; devices for detecting infectious agents that cause life-threatening diseases with high or suspected high risk of transmission; and devices for the critical monitoring of infection load in life-threatening diseases. The same pathogen assay can therefore sit in Class D or Class C depending on the claimed use. A hepatitis assay marketed for diagnosis may be Class C, while the same analytical principle claimed for blood donor screening is Class D.

Insight 2: Rule 2 is structured as Class C in principle, with Class D exceptions.

Blood grouping and tissue typing are in principle Class C. However, once a device is intended to determine markers of the ABO system (A, B, AB), the Rh system (RH1(D), RHW1, RH2(C), RH3(E), RH4(c), RH5(e)), the Kell system (Kel1(K)), the Kidd system (JK1, JK2) or the Duffy system (FY1, FY2), it rises to Class D. These five marker families are precisely among the targets covered by the common specification in Implementing Regulation (EU) 2022/1107. Products that only partially touch blood grouping should still be checked marker by marker against this list before a class is recorded.

Insight 3: the 13 purposes of Rule 3 are the main gateway into Class C.

Rule 3 covers, among others: detection of sexually transmitted agents; detection of infectious agents in cerebrospinal fluid or blood with no high transmission risk; detection where an erroneous result could cause death or severe disability; antenatal immune status screening; determination of infection or immune status where an erroneous result would lead to a life-threatening therapeutic decision; companion diagnostics; disease staging under comparable life-threatening decisions; cancer screening, diagnosis or staging; human genetic testing; monitoring of medicinal products, substances or biological components under comparable life-threatening decisions; management of patients with life-threatening diseases or conditions; antenatal screening for congenital disorders in the embryo or foetus; and neonatal screening for congenital disorders which, undetected and untreated, would lead to life-threatening situations or severe disabilities. Reading all thirteen purposes against the intended-use wording is mandatory for any assay suspected of Class C.

Insight 4: Rule 5 Class A has only three categories and is narrower than assumed.

Rule 5 covers: general laboratory products, accessories without critical characteristics, buffers, washing solutions, general culture media and histology staining media that the manufacturer makes suitable for a specific IVD procedure; instruments specifically intended by the manufacturer to be used in IVD procedures; and specimen receptacles. A common misjudgement is to place reagents carrying analyte-specific claims into Class A as well; such reagents fall under Rule 6 and are Class B. The boundary between Rule 5 and Rule 6 is the presence of an analyte-specific claim, which should be checked against the instructions for use, not the product catalogue.

4. Practical recommendations

1. Work through the rules in order and exclude them one by one, instead of applying a class by analogy from similar products.
2. Run a consequences test on the claims text: if the result were wrong, would it cause death, severe disability or a transmission risk? If yes, the device is at least Class C.
3. For blood grouping products, first determine whether the five marker families are touched, and only then decide between Class C and Class D.
4. For self-tests, apply Rule 4 first, then check whether the product falls within the Class B exceptions for pregnancy, fertility, cholesterol, urine glucose, urine red and white blood cells, and urine bacteria.
5. Re-run Rules 1 to 7 whenever the intended use changes, and archive the updated rationale.

5. Verification checklist

• □ Rules 1 to 7 compared one by one, with written reasons for applying or excluding each rule
• □ The Rule 1 consequences test completed and documented
• □ Blood grouping and tissue typing products checked against the five Class D marker families
• □ Self-tests checked against the four Class B exceptions in Rule 4
• □ The Class A scope of Rule 5 not extended beyond its wording
• □ Classification conclusions aligned with the Article 48 route and the technical documentation structure

Regulatory information verified as of 29 October 2026.

GRZAN conducts rule-by-rule classification analyses under Annex VIII, stress-tests claims text against Rules 1 to 7, and aligns classification outcomes with notified body expectations for the EU IVDR market. For tailored compliance support, contact info@grzanglobal.com.